Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
EOLS compared with VYNE: revenue, margins and what each company keeps, and the suppliers and customers both name
EOLS
Evolus, Inc.
Change
Mkt cap
Revenue
Revenue
VYNE
VYNE Therapeutics Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
EOLS
Evolus, Inc.
vs
VYNE
VYNE Therapeutics Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Supply-chain overlap
Desk
News
Calendar
Saved
Search
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only EOLS
3
—
Daewoong Pharmaceuticals
unlisted
supplier
—
Symatese
unlisted
supplier
—
Symatese Aesthetics S.A.S
unlisted
supplier
Shared
0
No disclosed counterparties: VYNE.
Only VYNE
0
None
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
EOLS
Evolus, Inc.
Change
7.28
▲
+1.61%
Mkt cap
$472.9M
Revenue
$84M
Q2 FY26
Revenue
$297M
FY25
VYNE
VYNE Therapeutics Inc.
Change
17.53
▼
−2.21%
Regular session
Nov 3 '26
Mkt cap
—
Revenue
—
Revenue
—
vs
Compare
Regular session
Nov 3 '26
EOLS
Evolus, Inc.
vs
VYNE
VYNE Therapeutics Inc.
7.28
▲
+1.61%
Price
17.53
▼
−2.21%
$472.9M
Mkt cap
—
Q2 FY26
$84M
Revenue
—
FY25
$297M
Revenue
—
Change
Change
EOLS
7.28
▲
+1.61%
vs
VYNE
17.53
▼
−2.21%
Regular session
Nov 3 '26